Twist Bioscience Launches $250 Million Public Stock Offering to Support R&D, Manufacturing Expansion, and Long-Term Growth Twist Bioscience Corporation (Nasdaq: TWST), a biotechnology company recognized for its synthetic DNA technology platform and expanding portfolio of genomics and life sciences products,…
FUJIFILM Biotechnologies Appoints Maja Pedersen as President to Lead Next Phase of Global Growth and Operational Excellence FUJIFILM Biotechnologies has announced a significant leadership transition designed to support the company’s continued expansion and long-term strategic growth. The global contract development…
Zai Lab’s DLL3-Targeting ADC Receives FDA Orphan Drug Designation for Neuroendocrine Carcinomas Zai Lab Limited has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci,…
EU Approval Positions Datroway® as the Only TROP2-Targeted Therapy with Overall Survival Benefit in First-Line Metastatic TNBC The European Commission (EC) has approved Datroway® (datopotamab deruxtecan) as a monotherapy for the first-line treatment of adults with unresectable or metastatic triple-negative…
Contineum Therapeutics Reports Second Quarter 2026 Financial Results and Reaffirms Clinical Development Milestones Across Inflammatory and Fibrotic Disease Pipeline Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing differentiated small-molecule therapies for inflammatory and fibrotic diseases with significant unmet…
Johnson & Johnson Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies for Immune-Mediated Diseases Johnson & Johnson has announced a broad strategic collaboration with Sail Biomedicines, a biotechnology company pioneering the development of in vivo chimeric antigen receptor…
VDyne Launches Pivotal TRIVITA Study, Treats First Patient with TriNova™ Transcatheter Tricuspid Valve Replacement System VDyne Inc., a privately held medical device company focused on advancing structural heart therapies, has reached an important milestone in the development of its innovative…
Vergent Bioscience Reports Promising Phase 2B Results for Abenacianine, Advancing Real-Time Tumor Imaging During Lung Cancer Surgery Vergent Bioscience, a clinical-stage biotechnology company focused on developing innovative tumor-targeted imaging technologies, has announced the publication of encouraging clinical data supporting its…
Secretome Therapeutics Strengthens Executive Leadership Team to Advance Rare Disease Pipeline and Regenerative Medicine Platform Secretome Therapeutics, a clinical-stage biotechnology company developing regenerative therapies derived from neonatal cardiac progenitor cells (nCPCs), has announced a significant expansion of its executive leadership…
Glaukos Completes Enrollment in Pivotal U.S. Study of PRESERFLO™ MicroShunt for Advanced Primary Open-Angle Glaucoma Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company dedicated to developing innovative treatments for glaucoma, corneal disorders, and retinal diseases, has announced the successful…
GCCL and GemPharmatech Form Strategic Alliance to Deliver Integrated Drug Discovery and Clinical Development Solutions GCCL, a South Korea-based provider of clinical trial sample analysis and central laboratory services, and GemPharmatech, a global leader in genetically engineered animal models and…
Arrowhead Pharmaceuticals Reports Positive Phase 3 Results for Plozasiran in Severe Hypertriglyceridemia, Demonstrating Significant Triglyceride Reduction and Lower Risk of Acute Pancreatitis Arrowhead Pharmaceuticals, Inc. has announced positive topline results from its pivotal global Phase 3 SHASTA-3 and SHASTA-4 clinical…